- Home
- PDX vs IOVA Comparison
PDX vs IOVA Comparison
Compare PDX & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDX
- IOVA
- Stock Information
- Founded
- PDX 2019
- IOVA 2007
- Country
- PDX NY
- IOVA United States
- Employees
- PDX N/A
- IOVA N/A
- Industry
- PDX Finance/Investors Services
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PDX Finance
- IOVA Health Care
- Exchange
- PDX Nasdaq
- IOVA Nasdaq
- Market Cap
- PDX 1.1B
- IOVA 975.1M
- IPO Year
- PDX N/A
- IOVA N/A
- Fundamental
- Price
- PDX $24.73
- IOVA $2.38
- Analyst Decision
- PDX
- IOVA Buy
- Analyst Count
- PDX 0
- IOVA 11
- Target Price
- PDX N/A
- IOVA $11.90
- AVG Volume (30 Days)
- PDX N/A
- IOVA 11.2M
- Earning Date
- PDX 01-01-0001
- IOVA 11-06-2025
- Dividend Yield
- PDX 4.95%
- IOVA N/A
- EPS Growth
- PDX N/A
- IOVA N/A
- EPS
- PDX N/A
- IOVA N/A
- Revenue
- PDX N/A
- IOVA $241,525,000.00
- Revenue This Year
- PDX N/A
- IOVA $67.40
- Revenue Next Year
- PDX N/A
- IOVA $56.32
- P/E Ratio
- PDX N/A
- IOVA N/A
- Revenue Growth
- PDX N/A
- IOVA 636.99
- 52 Week Low
- PDX $13.52
- IOVA $1.64
- 52 Week High
- PDX $21.05
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- PDX 54.77
- IOVA 49.08
- Support Level
- PDX $24.60
- IOVA $2.27
- Resistance Level
- PDX $25.00
- IOVA $2.46
- Average True Range (ATR)
- PDX 0.30
- IOVA 0.14
- MACD
- PDX 0.04
- IOVA 0.00
- Stochastic Oscillator
- PDX 66.25
- IOVA 49.09
About PDX PIMCO Dynamic Income Strategy Fund of Beneficial Interest
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited term, closed-end management investment company registered under the Investment Company. The fund's primary investment objective is to seek current income as a primary objective and capital appreciation as a secondary objective.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.